Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee

NCT04875754 is registered in ClinicalTrials.gov with ICM Biotech Australia Pty Ltd. as lead sponsor.

NCT NCT04875754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04875754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee
Lead sponsor
ICM Biotech Australia Pty Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
March 17, 2022
Completion date
February 20, 2026
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee